PubMed

Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA.

Popul Health Metr. 2007 Oct 29;5:11.PMID: 17967185 [PubMed - in process]Related articlesFree article

Multiparameter calibration of a natural history model of cervical cancer.

Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, Goldie SJ.

Am J Epidemiol. 2007 Jul 15;166(2):137-50. Epub 2007 May 25.PMID: 17526866 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States.

Kim JJ, Ortendahl J, Goldie SJ.

Ann Intern Med. 2009 Oct 20;151(8):538-45.PMID: 19841455 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.PMID: 19354343 [PubMed - indexed for MEDLINE]Related articles

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.PMID: 18513468 [PubMed - indexed for MEDLINE]Related articlesFree article

New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.

Syrjänen K.

Eur J Gynaecol Oncol. 2008;29(3):205-21.PMID: 18592782 [PubMed - indexed for MEDLINE]Related articles

Estimating the long-term clinical impact of cervical cancer vaccination in Taiwan.

Yen MS, You SL, Ferko N, Debicki D, Chen YC, Chou CY.

Int J Gynecol Cancer. 2009 Feb;19(2):281-8. Erratum in: Int J Gynecol Cancer. 2009 Aug;19(6):1153. You, Shan-Lin [corrected to You, San-Lin]. PMID: 19396010 [PubMed - indexed for MEDLINE]Related articles

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Insinga RP, Dasbach EJ, Elbasha EH.

BMC Infect Dis. 2009 Jul 29;9:119. Review.PMID: 19640281 [PubMed - indexed for MEDLINE]Related articlesFree article

Trade-offs in cervical cancer prevention: balancing benefits and risks.

Stout NK, Goldhaber-Fiebert JD, Ortendahl JD, Goldie SJ.

Arch Intern Med. 2008 Sep 22;168(17):1881-9.PMID: 18809815 [PubMed - indexed for MEDLINE]Related articlesFree article

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India.

Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ.

Br J Cancer. 2008 Jul 22;99(2):230-8. Epub 2008 Jul 8.PMID: 18612311 [PubMed - indexed for MEDLINE]Related articlesFree article

Development of an empirically calibrated model of gastric cancer in two high-risk countries.

Yeh JM, Kuntz KM, Ezzati M, Hur C, Kong CY, Goldie SJ.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1179-87.PMID: 18483340 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.

Reynales-Shigematsu LM, Rodrigues ER, Lazcano-Ponce E.

Arch Med Res. 2009 Aug;40(6):503-13.PMID: 19853192 [PubMed - in process]Related articles

Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty.

Van de Velde N, Brisson M, Boily MC.

Am J Epidemiol. 2007 Apr 1;165(7):762-75. Epub 2007 Feb 1.PMID: 17276976 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.

Gauthier A, Martín-Escudero V, Moore L, Ferko N, de Sanjosé S, Pérez-Escolano I, Catalá-López F, Ferrer E, Bosch FX.

Eur J Public Health. 2008 Dec;18(6):674-80. Epub 2008 Jul 19.PMID: 18641420 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ.

J Natl Cancer Inst. 2008 Mar 5;100(5):308-20. Epub 2008 Feb 26.PMID: 18314477 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.

Liu PH, Hu FC, Lee PI, Chow SN, Huang CW, Wang JD.

BMC Health Serv Res. 2010 Jan 11;10:11.PMID: 20064239 [PubMed - in process]Related articlesFree article

Modeling cervical cancer prevention in developed countries.

Kim JJ, Brisson M, Edmunds WJ, Goldie SJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K76-86. Review.PMID: 18847560 [PubMed - indexed for MEDLINE]Related articlesFree article

A review and critique of modelling in prioritising and designing screening programmes.

Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, Madan J.

Health Technol Assess. 2007 Dec;11(52):iii-iv, ix-xi, 1-145. Review.PMID: 18031651 [PubMed - indexed for MEDLINE]Related articlesFree article

HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness.

Coupé VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J.

Int J Cancer. 2009 Feb 15;124(4):970-8.PMID: 19035448 [PubMed - indexed for MEDLINE]Related articles

The impact of human papillomavirus vaccination on cervical cancer prevention efforts.

Massad LS, Einstein M, Myers E, Wheeler CM, Wentzensen N, Solomon D.

Gynecol Oncol. 2009 Aug;114(2):360-4. Epub 2009 May 1. Review.PMID: 19410282 [PubMed - indexed for MEDLINE]Related articles